Immuno-Oncology Market to Surge to US$ 111.64 Billion by 2034 with 16.5% CAGR, Driven by Innovative Therapies

The global immuno-oncology market, valued at US$ 24.17 billion in 2024, is projected to reach an impressive US$ 111.64 billion by 2034, growing at a robust CAGR of 16.5%, according to a comprehensive report by Fact.MR. Fueled by the rising global incidence of cancer and advancements in immunotherapy, this press release highlights the latest developments, key players, and competitive dynamics shaping the immuno-oncology landscape, optimized for Google News visibility.

Browse Full Report: https://www.factmr.com/report/immuno-oncology-market

Market Valuation and Growth Projections

The immuno-oncology market is experiencing significant growth, driven by the increasing global cancer burden and the adoption of preventive healthcare measures enabling early detection. Valued at US$ 24.17 billion in 2024, the market is expected to expand at a 16.5% CAGR, reaching US$ 111.64 billion by 2034. The surge in demand for innovative treatments like immune checkpoint inhibitors and cancer vaccines underscores the market's dynamic evolution.
Key Market Drivers

The global rise in cancer cases has spotlighted immuno-oncology as a vital solution, leveraging the human immune system to combat cancer cells. Innovations such as tumor-infecting viruses and cytokines are expanding treatment options, while regulatory bodies like the U.S. FDA are accelerating approvals for new immuno-oncology drugs, boosting market growth.

Additionally, the integration of immunotherapy with traditional treatments like chemotherapy enhances efficacy, driving demand for comprehensive cancer care solutions.

Segmentation Insights: Therapy Type, Therapeutic Area, and End User

The market is segmented by therapy type (Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Others), therapeutic area (Melanoma, Lung Cancer, Blood Cancers, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Others), and end user (Hospitals, Clinics, Ambulatory Surgical Centers). Immune checkpoint inhibitors dominate with a 91.4% market share in 2024, projected to grow at a 16.8% CAGR due to their proven efficacy. Melanoma leads therapeutic areas with a 36.9% share, followed closely by lung cancer at 31.7%. Hospitals remain the primary end users, driven by advanced infrastructure and specialized care.

Buy Report: https://www.factmr.com/checkout/9418

Regional Market Dynamics

North America commands a 71.0% market share in 2024, valued at US$ 17.16 billion, with a projected CAGR of 13.9% to reach US$ 62.97 billion by 2034. The United States leads due to robust healthcare infrastructure and significant R&D investments. East Asia, with a 12.5% share valued at US$ 3.01 billion in 2024, is set to grow at a 15.2% CAGR, reaching US$ 12.37 billion by 2034. China, with a 2024 valuation of US$ 1.68 billion and a 15.2% CAGR, is driven by government-backed cancer research initiatives. Japan, valued at US$ 0.77 billion in 2024, is projected to grow at a 15.5% CAGR, fueled by an aging population and regulatory support for novel therapies.

Competitive Landscape and Key Players

The immuno-oncology market is highly competitive, with global leaders driving innovation through strategic collaborations and R&D. Key players include Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., GSK Plc., Eli Lilly and Company, Fresenius Kabi AG, Pfizer Inc., AbbVie Inc.,

Genentech Inc., Sanofi, and AstraZeneca. Recent developments include:
• December 2023: Elpiscience Biopharma and Astellas Pharma signed a research agreement for cancer treatments, with potential earnings exceeding US$ 1.7 billion for Elpiscience upon meeting milestones.
• September 2023: GI Innovation (South Korea) partnered with Medidata Solutions (U.S.) to leverage AI and big data for developing two new drugs, GI-101 and GI-102.
• May 2023: KSQ Therapeutics (U.S.) and Takeda (Japan) expanded their partnership, increasing investment to advance immuno-oncology drug development.

These collaborations highlight the industry's focus on cross-border partnerships to enhance technological capabilities and market reach.

Industry Trends and Innovations

The immuno-oncology market is shaped by continuous innovation, including novel therapies like oncolytic viruses and cytokines, which expand treatment possibilities. The integration of immunotherapy with other cancer treatments enhances patient outcomes, while regulatory approvals from bodies like the FDA and Japan's Patent Office (e.g., Imugene's PD1-Vaxx patent in 2023) accelerate market entry for new drugs. Advances in early cancer detection and personalized medicine are further driving adoption, aligning with global healthcare trends toward precision oncology.

Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=9418

Challenges and Future Outlook

Challenges include high treatment costs, limiting accessibility in low-income regions, and manufacturing difficulties due to raw material shortages. Despite these hurdles, the market's outlook remains promising, driven by increasing cancer prevalence, regulatory support, and ongoing innovations in immunotherapy. The synergy of immuno-oncology with other treatments and the focus on personalized medicine are expected to sustain robust growth through 2034.

Check Out More Related Studies Published by Fact.MR:

Cancer Biomarkers Market
https://www.factmr.com/report/4587/cancer-biomarkers-market

Cancer Immunotherapy Market
https://www.factmr.com/report/4367/cancer-immunotherapy-market

Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR
We are a trusted research partner of 80% of Fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.